Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non‐small cell lung cancer: a prospective phase II study (GASTO‐1053)
Cancer Communications · 2025
DOI: 10.1002/cac2.70078 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Communications, 2025. Verfasst von Rui Zhou und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Bevacizumab, Brain Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
The prognosis for non‐small cell lung cancer (NSCLC) patients with extensive brain metastases (BMs) treated with radiotherapy alone remains poor. Based on the synergistic potential of radiotherapy and angiogenesis inhibitors, we initiated this phase II study to assess the efficacy and safety of combining bevacizumab (Bev) with fractionated stereotactic radiotherapy (FSRT) in managing extensive BMs in NSCLC patients who had stable extracranial disease.
Methods
Patients with extensive BMs from NSCLC, deemed unsuitable for stereotactic radiosurgery, were prospectively enrolled following multidisciplinary tumor board evaluation. Patients received FSRT (40 Gy in 10 fractions or 30 Gy in 5 fractions) in combination with Bev (7.5 mg/kg on day 1 prior to FSRT and on day 21 post‐FSRT). The primary endpoint was intracranial progression‐free survival (IPFS). Secondary endpoints included overall survival, progression‐free survival, quality of life (QOL), and toxicities. For comparison, NSCLC patients with extensive BMs treated with whole‐brain radiotherapy (WBRT) plus FSRT or FSRT alone were matched 1:1 with the study group (Bev + FSRT) using the propensity score matching.
Results
One hundred and six patients were included in the Bev + FSRT group, with a median follow‐up duration of 35.8 months. The median IPFS was 18.3 months (95% confidence interval, 15.2‐23.3 months). The Bev + FSRT group showed a significant improvement in IPFS compared to both the WBRT + FSRT group (9.6 months, P < 0.001) and the FSRT alone group (8.9 months, P < 0.001). Treatment was well tolerated, with grade 1 radiation necrosis in 1 patient. Bev + FSRT treatment significantly reduced tumor volume ( P < 0.001), peritumoral edema volume ( P = 0.004), and vascular leakage ( P < 0.001). Furthermore, QOL was significantly improved after Bev + FSRT treatment, particularly in patients with symptomatic extensive BMs.
Conclusion
These findings support the combination of Bev and FSRT as a safe and effective treatment strategy for extensive BMs in NSCLC patients, offering improved intracranial disease control and symptom relief while avoiding the neurotoxicity associated with WBRT. A randomized trial is warranted to validate the findings of the current study.
Trial registration
ClinicalTrials.gov, NCT04345146. Registration date: 2020‐02‐22.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
- State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P. R. China.
- Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, P. R. China.
- Lung Cancer Institute of Sun Yat-sen University, Guangzhou, Guangdong, P. R. China.
- Guangdong Association Study of Thoracic Oncology, Guangzhou, Guangdong, P. R. China.
- Department of Oncology, Laboratory of Immunity, Inflammation & Cancer, The First Affiliated Hospital of Chongqing Medical University, Chongqing, P. R. China.
ORCID-Profile: Hui Liu, Likun Chen
Zitieren
APA
Zhou, R., Zheng, S., Wang, D., Dong, F., Zhang, H., Zhang, T., Luo, Q., Liu, B., Liu, H., Zhang, J., Liu, F., Wang, B., Chen, L., Mou, Y., Peng, K., Qiu, B., & Liu, H. (2025). Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non‐small cell lung cancer: a prospective phase II study (GASTO‐1053). Cancer Communications. https://doi.org/10.1002/cac2.70078
Vancouver
Zhou R, Zheng S, Wang D, Dong F, Zhang H, Zhang T, et al. Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non‐small cell lung cancer: a prospective phase II study (GASTO‐1053). Cancer Communications. 2025. doi:10.1002/cac2.70078
BibTeX
@article{Zhou2025,
author = {Zhou, Rui and Zheng, Shiyang and Wang, Daquan and Dong, Fang and Zhang, Hongmei and Zhang, Tao and Luo, Qiaoting and Liu, Biaoshui and Liu, Hui and Zhang, Jun and Liu, Fangjie and Wang, Bin and Chen, Likun and Mou, Yonggao and Peng, Kangqiang and Qiu, Bo and Liu, Hui},
title = {Efficacy and safety of combining bevacizumab and fractionated stereotactic radiotherapy for extensive brain metastases in patients with non‐small cell lung cancer: a prospective phase II study (GASTO‐1053)},
journal = {Cancer Communications},
year = {2025},
doi = {10.1002/cac2.70078}
}
EUVIMED